Literature DB >> 22481531

Construction, expression and refolding of a bifunctional fusion protein consisting of C-terminal 12-residue of hirudin-PA and reteplase.

Ling Gao1, Chun Zhang, Lingling Li, Lan Liang, Xuan Deng, Wutong Wu, Zhiguo Su, Rong Yu.   

Abstract

To obtain a bifunctional protein simultaneously showing bioactivity of anticoagulant and fibrinolytic for use in the treatment of thrombotic diseases, we constructed a fusion protein (HV12p-rPA) containing C-terminal 12-residue of hirudin-PA (HV12p) and reteplase (rPA). The fusion protein, in which HV12p was linked to rPA via Gly-Gly-Gly, was successfully expressed in an inactive form of inclusion bodies in Escherichia coli. HV12p-rPA was identified by sodium dodecylsulfate-polyacrylamide gel electrophoresis. The expression level of HV12p-rPA was optimized by an orthogonal method and finally enhanced from 12 % to approximate 30 %. We also deeply investigated the condition of renaturation of HV12p-rPA, and the inactive protein was partly renatured through various conditions. The refolding efficacy of HV12p-rPA estimated by the recovery of fibrinolytic activity varied from 0.03 % to 16.6 % and the anticoagulant activity fluctuated in the range from 41 to 2,297 ATU/mg. Bioassays indicated that the resulted fusion protein, as expected, exhibited both fibrinolytic and anticoagulant activities. These works laid a foundation for further characterization of HV12p-rPA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22481531     DOI: 10.1007/s10930-012-9407-8

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  32 in total

1.  The use of hirudin as universal anticoagulant in haematology, clinical chemistry and blood grouping.

Authors:  H D Menssen; K Melber; N Brandt; E Thiel
Journal:  Clin Chem Lab Med       Date:  2001-12       Impact factor: 3.694

Review 2.  [Change of concept and pathophysiology in acute coronary syndrome].

Authors:  Tomotaka Dohi; Hiroyuki Daida
Journal:  Nihon Rinsho       Date:  2010-04

Review 3.  Antithrombotic and thrombolytic therapy for ischemic stroke.

Authors:  Lenore C Ocava; Manjeet Singh; Samit Malhotra; Daniel M Rosenbaum
Journal:  Clin Geriatr Med       Date:  2006-02       Impact factor: 3.076

Review 4.  Advances in refolding of proteins produced in E. coli.

Authors:  H Lilie; E Schwarz; R Rudolph
Journal:  Curr Opin Biotechnol       Date:  1998-10       Impact factor: 9.740

Review 5.  Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator.

Authors:  R W Smalling
Journal:  Eur Heart J       Date:  1997-12       Impact factor: 29.983

6.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

Review 7.  Chemistry for peptide and protein PEGylation.

Authors:  M J Roberts; M D Bentley; J M Harris
Journal:  Adv Drug Deliv Rev       Date:  2002-06-17       Impact factor: 15.470

8.  Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis.

Authors:  Maarten G Lansberg; Erich Bluhmki; Vincent N Thijs
Journal:  Stroke       Date:  2009-05-28       Impact factor: 7.914

9.  In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

10.  The structure of a complex of recombinant hirudin and human alpha-thrombin.

Authors:  T J Rydel; K G Ravichandran; A Tulinsky; W Bode; R Huber; C Roitsch; J W Fenton
Journal:  Science       Date:  1990-07-20       Impact factor: 47.728

View more
  5 in total

1.  Computational design, functional analysis and antigenic epitope estimation of a novel hybrid of 12 peptides of hirudin and reteplase.

Authors:  Yingting Cai; Jingxiao Bao; Xingzhen Lao; Heng Zheng; Jianhua Chen; Rong Yu
Journal:  J Mol Model       Date:  2015-08-13       Impact factor: 1.810

2.  Expression of the recombinant plasminogen activator (reteplase) by a non-lytic insect cell expression system.

Authors:  S Aflakiyan; H Mir Mohammad Sadeghi; M Shokrgozar; M Rabbani; S Bouzari; A Jahanian-Najafabadi
Journal:  Res Pharm Sci       Date:  2013-01

3.  Molecular cloning of Reteplase and its expression in E. coli using tac promoter.

Authors:  Safieh Aghaabdollahian; Mohammad Rabbani; Kamran Ghaedi; Hamid Mir Mohammad Sadeghi
Journal:  Adv Biomed Res       Date:  2014-09-12

4.  Comparison of Three Escherichia coli Strains in Recombinant Production of Reteplase.

Authors:  Mehrnoosh Fathi-Roudsari; Asal Akhavian-Tehrani; Nader Maghsoudi
Journal:  Avicenna J Med Biotechnol       Date:  2016 Jan-Mar

Review 5.  Pharmacological Activities and Mechanisms of Hirudin and Its Derivatives - A Review.

Authors:  Chen Junren; Xie Xiaofang; Zhang Huiqiong; Li Gangmin; Yin Yanpeng; Cao Xiaoyu; Gao Yuqing; Li Yanan; Zhang Yue; Peng Fu; Peng Cheng
Journal:  Front Pharmacol       Date:  2021-04-16       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.